

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.14 Billion in January

保瑞公告 1 月自結合併營收新台幣 11 億 4 仟萬元

Taipei, Taiwan, February 10, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for January 2026 reached NT\$1.14 billion, a 30.2% decrease over same period last year. While the decrease is not representative of the underlying fundamentals, it is within Management’s expectations as Maryland fill and finish facility had its timed shut-down starting the second half of January and will last for 3 to 4 weeks for maintenance, and the unclear competitive landscape of DLS resulting in >50% year-over-year decline of the product as wholesalers continued to monitor new market entrant behavior for the majority of January.

台北，台灣，2026 年 2 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 1 月自結合併營收為新台幣 11 億 4 仟萬元，較去年同期衰退 30.2%；儘管開年浮現挑戰，公司認為此營收水平無法代表全年趨勢，衰退主係馬里蘭州針劑廠自一月下旬進入為期 3 至 4 周的年度檢修，以及全球銷售業務中胃食道逆流學名藥 DLS 經銷商客戶持續觀察競爭對手價格趨勢所致。

Looking ahead, the Company expects these uncertain market conditions to improve from March onwards as new product launches at Upsher-Smith, peak activity anticipated at Maryland facility, and overall commercial indicators for CDMO business in 2026 trending favorably to play a vital role in profitable growth.

展望今年，保瑞以目前能見度評斷第一季底應是反轉周期的開始，將兢兢業業就 Upsher-Smith 公司的新產品上市、馬里蘭州針劑廠的訂單落實以及整體 CDMO 在手訂單如期交付全力以赴，為 2026 年獲利與增長打下良好基礎。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success



"certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdmo.com>

關於保瑞：

保瑞藥業股份有限公司 (股票代碼：6472.TW與BORAY.OTCQX) 成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO (委託開發與製造服務) 與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdmo.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com